Table 1.
Emerging epigenetic therapies in HCC. Clinicaltrials.gov accessed on 15th July 2016
| Agent | Phase | Target | Primary outcome | Clinical trials identifier |
|---|---|---|---|---|
| SGI-110 | II | DNMT | DCR at 16 weeks | NCT01752933 |
| CUDC-101 | Ib | HDAC/EGFR/Her2 | AE | NCT01171924 |
| Vorinostat | I | HDAC | MTD | NCT01075113 |
| MRX34 | I | miR-RX34 | MTD | NCT01829971 |
| PXD-101 | I/II | HDAC | MTD/TR | NCT00321594 |
| Resminostat | II | HDAC | PFSR at 12 weeks | NCT00943449 |
AE, adverse events; DCR, Disease Control Rate; DNMT, DNA methyltransferase; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor 2; MTD, maximum tolerated dose; PRSF, progression-free survival rate; TR, tumour response.